All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Many HIV patients currently do not have reliable access to essential diagnostic laboratory tests, including CD4, clinical chemistry, hematology, viral load, and diagnosis of common co-infections. CD4 testing is critical for identifying patients most in need of clinical care and antiretroviral therapy (ART) \[[@pone.0155256.ref001]--[@pone.0155256.ref004]\]. While there is a progressive move away from CD4 cell count as the main way to determine eligibility for ART \[[@pone.0155256.ref005]\], CD4 cell count testing still has an important role to play in baseline risk assessment, prioritizing patients when limited ART drug supplies exist, and diagnosing treatment failure in settings where access to viral load monitoring is limited \[[@pone.0155256.ref006],[@pone.0155256.ref007]\]. Furthermore, CD4 testing remains beneficial for HIV disease and opportunistic infection management of patients on ART.

Conventional laboratory-based CD4 testing presents several key challenges including use of complicated equipment that is poorly adapted for resource-limited settings, requires un-interrupted power supply, cold chain logistics for reagents, regular technical support and maintenance, and a high skill level for operation as well as large capital outlay for equipment. Due to these constraints, conventional CD4 testing is limited to higher tiered laboratory settings that often limit the access to testing. Transport of whole blood samples to centralized laboratories and return of results to clinical sites is a challenge in resource-limited settings often resulting in invalid specimens, inaccurate results, long turn around times for results or lost results. Delays caused by conventional testing and result delivery can lead to patients being lost before ART initiation \[[@pone.0155256.ref008]\].

Several studies have highlighted the need to improve patient retention prior to ART initiation in the current cascade of care \[[@pone.0155256.ref008]--[@pone.0155256.ref011]\]. Just over half of known HIV-positive patients receive a CD4 test result, while less than three-quarters of patients determined eligible are initiated on ART \[[@pone.0155256.ref009]--[@pone.0155256.ref011]\]. Pre-ART retention has been substantially low at under 50% in previous meta-analyses \[[@pone.0155256.ref009],[@pone.0155256.ref011]\]. The requirement of multiple visits for sample collection, results received, and clinical decision-making can lead to increased transportation costs and distances, long waiting times, and the requirement to take time away from work, all of which are associated with loss \[[@pone.0155256.ref008]\].

POC diagnostic technologies may alleviate some of these burdens on the health care system by decentralizing care and testing, providing immediate test results, and allowing for expedited clinical decisions. Several POC CD4 technologies are currently on the market \[[@pone.0155256.ref012]\] and several are in the development pipeline. POC CD4 technologies can reduce the number of trips to the health care facility required of patients in the pre-ART staging process, thus decreasing costs, effort and time away from work. Same day HIV diagnosis, CD4 testing, and ART eligibility assessments can lower the pre-ART attrition observed in most high HIV burden settings \[[@pone.0155256.ref013]\].

A previous systematic review published in 2013 reported improved retention along the testing and treatment cascade with the introduction and use of POC CD4 technologies \[[@pone.0155256.ref014]\]; however, this review was conducted early in the adoption of POC CD4 and the number of studies contributing to the review was small and limited in the number of outcomes it was able to assess. We conducted this systematic review and meta-analysis to update the patient impact of POC CD4 compared to conventional laboratory-based testing to support the 2016 revision of the World Health Organization (WHO) guidelines for the treatment and care of people living with HIV.

Methods {#sec006}
=======

Search strategy and study selection {#sec007}
-----------------------------------

Standard global guidelines were followed for the search strategy and study selection including the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@pone.0155256.ref015]\] ([S1 Fig](#pone.0155256.s001){ref-type="supplementary-material"}). PubMed and EMBASE databases were searched from 1 January 2005 to 15 April 2015. Search terms were developed using the PICO question format (population, intervention, comparator, outcome). The search terms were, therefore, broken into four categories: HIV (population), POC (intervention), CD4 (intervention/comparator), and outcomes. Characteristics of POC technologies as well as manufacturer names were included to maximize study identification as well as an extensive list of outcomes ([S2 Fig](#pone.0155256.s002){ref-type="supplementary-material"}). Conference abstracts within the search dates from the Conference on Retroviruses and Opportunistic Infections (CROI), International Conference on AIDS and STIs in Africa (ICASA), International AIDS Society (IAS), and AIDS Conference and bibliographies were also screened and reviewed for possible inclusion. Search terms included characteristics of POC technologies, outcome terms, and manufacturer names to maximize study identification. Two independent reviewers screened all titles and abstracts for eligibility. Studies were included if they compared the impact of POC to laboratory-based CD4 testing in HIV-positive patients. No geographical region or age restrictions were applied. Only English language studies were considered for inclusion. Data was extracted from each study included: the POC CD4 technology used, sample size, test setting, study dates, and key outcomes as defined in the study protocol. Studies were assessed for quality, bias and applicability using the QUADAS-2 guidelines \[[@pone.0155256.ref016]\].

Data analysis {#sec008}
-------------

The primary outcomes of interest were time and retention along the testing and treatment cascade. Secondary outcomes included cost-effectiveness and acceptability. To determine the presence of between-study heterogeneity, the Q-statistic was calculated \[[@pone.0155256.ref017]\]. Random effects models were used to estimate the pooled summary measures for turnaround time, proportions of retention, risk ratios, and 95% confidence intervals. For the random effects model of proportions, the metaprop command was used in Stata with a continuity correction value of 0.5 and exact confidence intervals. To calculate risk ratios, the metan command was used, specifying use of the DerSimonian and Laird method using the inverse-variance fixed effect model for the estimate of heterogeneity. Weighted averages were used to compare continuous outcomes for patients tested with a POC technology compared to those tested with a conventional laboratory-based technology.

Two researchers independently performed the statistical analysis to ensure accuracy. Graphic representations were completed in GraphPad Prism v6.0 (La Jolla, California, USA) and analyses were completed in Stata 13 (College Station, Texas, USA).

Results {#sec009}
=======

Study characteristics and assessment {#sec010}
------------------------------------

The search strategy yielded 30 studies relevant to the study question ([Fig 1](#pone.0155256.g001){ref-type="fig"} and [Table 1](#pone.0155256.t001){ref-type="table"}) \[[@pone.0155256.ref013],[@pone.0155256.ref018]--[@pone.0155256.ref046]\]. Almost 40,000 total patients were included in the analysis, while the median sample size per study was 830 HIV-positive patients. All studies included adults; however, one study focused on youth between 12 and 25 years of age. Five studies included pregnant women as the primary population. The included studies spanned eight countries, most within sub-Saharan Africa. All studies were conducted between 2009 and 2015. Two POC CD4 technologies were included with 25 of 27 studies using the Alere Pima POC CD4. There were three randomized control trials, four prospective observational studies, 17 retrospective observational studies, and six cost-effectiveness or costing studies.

![PRISMA diagram of search outcome and included studies.](pone.0155256.g001){#pone.0155256.g001}

10.1371/journal.pone.0155256.t001

###### Study characteristics.

![](pone.0155256.t001){#pone.0155256.t001g}

  \#   Author       Journal          Year          Countries of study     Type of study                 Years of study   Site type            Population                POC technology   \# of participants
  ---- ------------ ---------------- ------------- ---------------------- ----------------------------- ---------------- -------------------- ------------------------- ---------------- --------------------
  1    Barnabas     Lancet           2014          South Africa, Uganda   prospective observational     2011--2013       home-based           adults                    Alere Pima       3545
  2    Bassett      PLoS One         2014          South Africa           cost-effectiveness            2010--2011       mobile clinic        adults                    Alere Pima       NA
  3    Brown        IAS poster       2013          Tanzania               retrospective observational   2011--2012       clinics              adults                    Alere Pima       NI
  4    Cassim       PLoS One         2014          South Africa           costing                       2012--2013       NA                   adults                    Alere Pima       NA
  5    Chien        IAS poster       2013          Uganda                 retrospective observational   2011--2012       clinics              adults                    Alere Pima       NI
  6    Ciaranello   PLoS One         2015          South Africa           cost-effectiveness            NA               NA                   infants, pregnant women   generic          NA
  7    De Schacht   IAS abstract     2012          Mozambique             retrospective observational   2010--2011       EGPAF clinics        pregnant adults           Alere Pima       3410
  8    Desai        CROI poster      2015          Kenya                  prospective RCT               2013--2014       home-based/clinics   adults                    Alere Pima       770
  9    Dhoot        IJSA             2013          UK                     retrospective observational   2011--2012       NI                   adults                    Alere Pima       44
  10   Faal         JAIDS            2011          South Africa           prospective RCT               2009             clinic               adults                    BD FACSCount     344
  11   Fajardo      AIDS poster      2014          9 sSA                  retrospective observational   2011--2013       MSF clinics          adults                    Alere Pima       25749
  12   Grundy       presentation     unpublished   NA                     cost-effectiveness            NI               NI                   NA                        generic          NA
  13   Hatzold      IAS abstract     2011          Zimbabwe               retrospective observational   NI               PSI clinics          adults                    not indicated    182
  14   Herbert      HIV Medicine     2011          UK                     retrospective observational   2010--2011       clinic               adults                    Alere Pima       200
  15   Hyle         PLoS One         2014          Mozambique             cost-effectiveness            NA               NA                   adults                    Alere Pima       NA
  16   Jani         Lancet           2011          Mozambique             retrospective observational   2009--2010       clinics              adults                    Alere Pima       1021
  17   Jani         AIDS             2015          Mozambique             retrospective observational   2013--2014       clinics              adults                    Alere Pima       103795
  18   Larson       PLoS One         2012          South Africa           costing                       NA               mobile clinic        adults                    Alere Pima       NA
  19   Larson       JAIDS            2012          South Africa           retrospective observational   2010--2011       mobile clinic        adults                    Alere Pima       508
  20   Larson       AIDS Res Tre     2013          South Africa           retrospective observational   2008--2010       clinic               adults                    Alere Pima       897
  21   Larson       IAS abstract     2011          South Africa           retrospective observational   2010             clinic               adults                    BD FACSCount     538
  22   Muchedzi     IAS abstract     2012          Zimbabwe               retrospective observational   2011             EGPAF clinics        pregnant adults           Alere Pima       2310
  23   Myer         JAIDS            2015          South Africa           prospective observational     2010--2013       clinic               pregnant adults           Alere Pima       19432
  24   Myer         AIDS Care        2012          South Africa           retrospective observational   2011             clinic               pregnant adults           Alere Pima       2290
  25   Obi          unclear          2013          UK                     prospective observational     NI               hospital             adults                    Alere Pima       199
  26   Patten       JIAS             2013          South Africa           retrospective observational   2010--2012       clinics              youth, 12-25y             Alere Pima       576
  27   Rioja        IAS poster       2013          Cameroon               retrospective observational   2012             hospitals            adults                    Alere Pima       NI
  28   Rosen        CROI poster      2015          South Africa           prospective RCT               2013--2014       clinics              adults                    Alere Pima       598
  29   Tsibolane    in preparation   2014          South Africa           retrospective observational   2014             clinics              adults                    Alere Pima       1492
  30   van Rooyen   JAIDS            2013          South Africa           prospective observational     2011--2012       home-based           adults                    Alere Pima       671

NI: not indicated

NA: not applicable

Overall, there was a moderate risk of bias due to potential confounding temporal, facility- or individual-level factors. Most studies were observational cross-sectional studies. Participant samples in most studies were not consecutively recruited or studies failed to report the process of patient recruitment (70%). The rationale for facility selection was not indicated or not randomized in most studies (72%). Some studies used a pre-post analysis while others compared different groups of facilities with and without POC CD4 devices. There were some potential limitations in geographical applicability: most (90%) studies were carried out in Africa in field settings and 50% were carried out in one country (South Africa). Additionally, most studies (78%) did not include POC CD4 testing using finger-prick samples or failed to report the specimen type.

Timeliness of testing and ART initiation {#sec011}
----------------------------------------

POC CD4 technologies reduced test turnaround times from HIV diagnosis to CD4 test and HIV diagnosis to ART initiation when compared with conventional laboratory-based testing ([Fig 2](#pone.0155256.g002){ref-type="fig"}). The time from HIV diagnosis to CD4 test had a pooled mean of 10.5 days with conventional laboratory-based testing. This was reduced to a pooled mean of 0.1 days with POC CD4 testing. The time from HIV diagnosis to ART initiation was reduced from a mean of 31.5 days with conventional laboratory-based testing to a mean of 9.0 days with POC CD4 testing.

![Mean turnaround times in days between two stages in the testing and treatment cascade.\
(a) CD4 test conducted to CD4 test result received, (b) HIV diagnosis and ART initiation. Orange bars represent the mean turnaround times for conventional laboratory-based testing, while blue bars represent the mean turnaround times for POC CD4 testing.](pone.0155256.g002){#pone.0155256.g002}

Retention along the testing and treatment cascade {#sec012}
-------------------------------------------------

POC CD4 improved retention between several steps along the testing and treatment cascade. Pooled proportions of patients reaching the following step in the cascade were significantly higher for POC CD4 compared to conventional laboratory-based testing ([Fig 3](#pone.0155256.g003){ref-type="fig"}). The proportion of patients who received a CD4 test after HIV testing increased from 70% (95% CI: 62--78%) with conventional laboratory-based testing to 87% (95% CI: 83--91%) with POC CD4 testing (RR: 1.21; 95% CI: 1.15--1.27; p\<0.001). Significantly more patients received their CD4 test result after POC testing (95%; 95% CI: 94--97%) compared to conventional laboratory-based testing (88%; 95% CI: 86--90%) (RR: 1.07; 95% CI: 1.04--1.19; p\<0.001). Patients had a 58% higher likelihood of being retained prior to CD4 testing with POC compared to conventional laboratory-based testing, 83% (95% CI: 76--90%) versus 53% (95% CI: 41--65); RR: 1.58; 1.35--1.85; p\<0.001). Additionally, significantly more patients were retained between CD4 testing and ART initiation with POC CD4 (72%; 95% CI: 59--85) compared with conventional laboratory-based testing (60%; 95% CI: 47--74) (RR: 1.16; 1.03--1.31; p = 0.01).

![Proportions and risk ratios of patients reaching the next stage in the testing and treatment cascade.\
(a) Proportions of patients reaching the next stage in the testing and treatment cascade. Orange dashes and bars represent the estimated proportion of retention and 95% confidence intervals of patients receiving conventional laboratory-based testing, while blue dashes and bars represent the estimated proportion of retention and 95% confidence intervals of patients receiving POC CD4 testing. (b) Risk ratios for the likelihood of retention until the next stage in the testing and treatment cascade.](pone.0155256.g003){#pone.0155256.g003}

Literature review of cost-effectiveness of POC CD4 {#sec013}
--------------------------------------------------

Four studies looked at the cost-effectiveness of POC CD4 testing. A study from Mozambique found a 0.7-year increase in the projected life expectancy using POC CD4 compared to conventional laboratory-based testing \[[@pone.0155256.ref031]\]; POC CD4 was found to be cost-effective with an ICER/life year saved of \$500. In a mobile unit in South Africa, an increase of 0.71 years and an ICER/life year saved of \$2,400 USD was estimated to result from the inclusion of POC CD4 testing \[[@pone.0155256.ref019]\] as part of the overall mobile unit. Another study from South Africa focused on maternal to child transmission (MTCT) rates and observed a 0.4% reduction in transmission with the use of POC CD4 over conventional laboratory-based testing; however, this study was completed before Option B (ART for pregnant and breastfeeding women during the mother-to-child transmission risk period and maintain after cessation of breastfeeding for those eligible based on their own health) or Option B+ (lifelong ART for all pregnant and breastfeeding women living with HIV) were introduced \[[@pone.0155256.ref022],[@pone.0155256.ref047]\]. Finally, a study from Malawi reported the cost per life saved with POC CD4 testing was \$148.30 compared to \$165.50 with conventional laboratory-based testing \[[@pone.0155256.ref028]\].

Literature review of acceptability {#sec014}
----------------------------------

Two studies, both from the UK, assessed the acceptability of POC CD4 testing. The first study, reported that \>80% of patients found waiting 20 minutes for test results acceptable, while approximately 60% found the POC test preferable to conventional laboratory-based testing \[[@pone.0155256.ref030]\]. The second study found POC CD4 testing to be highly accepted compared to conventional laboratory-based testing; both new and stable patients reported significant time reductions of clinic visits \[[@pone.0155256.ref041]\].

Discussion {#sec015}
==========

POC CD4 technologies have been implemented in over 2,000 health care facilities in at least 70 countries around the world with large, well-established programs in several countries in sub-Saharan Africa, Southeast Asia, and Central and South America \[[@pone.0155256.ref048]\]. This level of scale-up has provided a good opportunity to assess the clinical impact of POC CD4 testing. Many studies have reported positive impact on turnaround times, rates of ART initiation, and loss to follow up when POC CD4 is used compared to conventional laboratory testing in the current public health approach of utilizing CD4 as a gateway to ART.

A previous systematic review of 15 published studies reported an increased likelihood of having CD4 measured (OR = 4.1), an increased likelihood of receiving a CD4 result (OR = 2.8), an increased likelihood of proceeding from CD4 to ART initiation (OR = 1.8), a reduced test turn-around time by 9 days and a reduced time from CD4 testing to receiving the result by 17 days \[[@pone.0155256.ref014]\]. Consistent with these previous findings, our review found that POC CD4 improved the timeliness of testing and retention of patients along the testing and treatment cascade. Time between HIV diagnosis and CD4 test and between HIV diagnosis and ART initiation were substantially reduced with the use of POC CD4 when compared to conventional laboratory-based CD4 testing. Retention along the testing and treatment cascade was significantly improved with POC CD4 testing, notably between HIV testing to CD4 testing, receipt of CD4 results, and CD4 testing and ART initiation. Finally, there was some evidence that POC CD4 was cost-effective and acceptable.

There are several limitations to this review. First, although both observational and randomized evidence was sought, most of the included studies were observational; such study designs may better reflect implementation practice, but are at higher risk of bias. All but five studies used the Alere Pima™ POC CD4 platform as the intervention. While it is not anticipated that different POC CD4 technologies with similar test times and error rates would result in variable patient impact, this could not be assessed with the limited data available. Also, participants in most studies were not consecutively recruited or failed to report the process of patient recruitment, while the rationale for facility selection was not indicated or not randomized in most studies. The possibility exists that some studies may suffer from patient or facility selection bias. Another limitation is that the applicability of these findings beyond Africa is unclear as almost all studies were carried out in Africa, despite at least 70 countries and many resource-limited countries having adopted POC CD4 technologies \[[@pone.0155256.ref048]\]. Finally, the findings were heterogeneous across studies ([S3 Fig](#pone.0155256.s003){ref-type="supplementary-material"}). Little detail was provided on the function of the conventional testing systems; however, the variable findings were likely due to significantly diverse quality of the conventional laboratories and related systems across different settings and countries included in the analysis.

The cost-effectiveness of POC CD4 is well-defined; however, affordability analyses with clear, detailed costing would allow stakeholders to carefully consider the adoption and scale-up of POC CD4 in light of changing guidelines and restricted budgets. Also, operational implementation guidance and tools based on best practice experiences would be valuable to inform use of these technologies. Furthermore, guidelines and optimal models for ensuring high quality, reliable test results for both rapid and point of care tests would be valuable.

Recent WHO Consolidated ART guidelines recommend treating all patients living with HIV, regardless of CD4 count, and using viral load testing to monitor patients on ART \[[@pone.0155256.ref005],[@pone.0155256.ref047]\]. CD4 testing is, however, recommended for monitoring opportunistic infections of unstable or sick patients. The frequency and utility of CD4 testing may, therefore, decline in the future; however, many national programs in high HIV burden countries have only begun implementing routine viral load testing and few have adopted the treat all recommendation into national policies.

Widespread uptake and decentralization of rapid diagnostic tests for major public health challenges, including HIV, tuberculosis and malaria, have led to significant gains in health provision and greater access to treatment, particularly in resource-limited settings \[[@pone.0155256.ref049]\]. While centralized laboratory networks are important for high throughput sample processing and quality control, they are unable to provide access to same day testing services to all patients in need. Also, sample transportation networks can be weak in many resource-limited settings resulting in long test turnaround times. POC tests are rapid, easy to use, and significantly improve retention of patients along the testing and treatment cascade and reduce the time from diagnosis to treatment compared to conventional laboratory-based testing. For POC tests to contribute maximally to laboratory networks, however, supportive systems such as supply chain, training and monitoring, quality assurance, service and maintenance, and data management must be built into the testing network and strengthened for improved patient care.
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